Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

The Lancet Neurology in conversation with - A podcast by The Lancet Group - Thursdays

Categories:

Education

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.Read the full article:Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancet...